lymphoma

CAR T-cell therapies in treating lymphoma: Pros and consCatherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Three things health execs need to know about CAR T-cell therapyHere’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
Psoriasis patients have a heightened risk of malignant lymphomaPatients with psoriasis are more likely than the general population to receive a diagnosis of malignant lymphoma. Why? Cutaneous T-cell lymphoma is misdiagnosed as psoriasis and can also be mistaken for atopic dermatitis due to similarities in the skin manifestation.
Four new treatments for acute myeloid leukemia to watchKey takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.
Four new treatments for acute myeloid leukemia to watchKey takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.
This is why you should be excited for upcoming cancer researchAcute myeloid leukemia experts share promising new developments on the oncology horizon.
Targeted vitreoretinal lymphoma therapies mimic other approaches
Targeted vitreoretinal lymphoma therapies mimic other approachesVitreoretinal lymphomas are both deceptive and deadly. While there are only about 350 cases reported annually in the United States, median survival is less than 5 years, said Rajesh C. Rao, MD.
First therapy approved for rare blood cancerFDA recently granted accelerated approved for ibrutinib (Imbruvica, Janssen, Pharmacyclics), the first treatment for patients with a certain type of lymphoma.
Promising treatment developments in lymphoma immunotherapiesIn this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.
Breakthrough lymphoma drug on the horizonFDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma.